Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.03 USD | +1.62% | +1.41% | +6.79% |
23/04 | Sophia Genetics Says Nigeria's Syndicate Bio Signs on to Implement Liquid Biopsy Offering | MT |
23/04 | SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's enterprise value to sales, at 3.44 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.79% | 328M | - | ||
+5.58% | 82.93B | B | ||
+3.69% | 76.85B | B+ | ||
-14.62% | 53.04B | B+ | ||
-24.56% | 46.55B | B- | ||
+31.16% | 50.15B | D+ | ||
+17.75% | 41.41B | D+ | ||
+55.21% | 35.63B | D+ | ||
-10.24% | 24.64B | C+ | ||
-21.24% | 23.04B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SOPH Stock
- Ratings SOPHiA GENETICS SA